InvestWiserPila Pharma AB
PILA · Nasdaq Stockholm · Healthcare
1.74SEK
−7.2%last day
Price as of 2 October 2026
Performance
1 month
+16.0%
1 year
−18.3%
3 years, per year
−5.9%
5 years, per year
−26.2%
Largest fall, 3 years
−91.0%
Below the peak now
−85.6%
Volatility, 1 year
96.9%
Return with dividends reinvested.
Key figures
P/E
negative earnings
P/B
3.8
Dividend yield
0.0%
Return on equity
−104.1%
Net margin
–
Market value
6 m USD
Quality, value and trend
Where Pila Pharma stands against every Nordic stock today. 100 is best.
57
Profitability and a sound balance sheet over time. Better than 57% of Nordic stocks.
4
The price measured against earnings, assets and cash flow. Better than 4% of Nordic stocks.
44
The price development over the past year. Better than 44% of Nordic stocks.
20
Quality, value and trend together. Better than 20% of Nordic stocks.
About Pila Pharma
Pila Pharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK.
Pila Pharma AB (publ) operates as a clinical stage biotech company in Sweden. The company develops XEN-D0501, a TRPV1 antagonist in Phase 2a trial for obesity, diabetes, and heart failure; Phase 1 trial for erythromelalgia, inflammation pain, and rare diseases; and preclinical trial for abdominal aorta aneurism and cardiovascular diseases. Pila Pharma AB (publ) was incorporated in 2014 and is headquartered in Malmö, Sweden.
See the full analysis in InvestWiser.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
See the full analysis